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Abstract Patients with pseudohypoparathyroidism type
Ib (PHP-Ib) present hypocalcemia and hyperphosphatemia,
as a consequence of a resistance to PTH action, through its
G-protein-coupled receptor, in the renal tubules. This
resistance results from tissue-specific silencing of the
G-protein alpha-subunit (Gsa), due to imprinting disruption
of its encoding locus—GNAS. In familial PHP-Ib, mater-
nally inherited deletions at the STX16 gene are associated
to a regional GNAS methylation defect. In sporadic PHP-
Ib, broad methylation changes at GNAS arise from
unknown genetic causes. In this study, we describe the
clinical presentation of PHP-Ib in four Portuguese patients
(two of whom were siblings), and provide further insight
for the management of patients with this disease. The
diagnosis of PHP-Ib was made after detection of GNAS
imprinting defects in each of the cases. In the siblings, a
regional GNAS methylation change resulted from a known
3.0 kb STX16 deletion. In the other two patients, the broad
methylation defects at GNAS, which were absent in their
relatives, resulted from genetic alterations that remain to be
identified. We report the first clinical and genetic study of
Portuguese patients with PHP-Ib. The genetic identification
of a hereditary form of this rare disease allowed an
early diagnosis, and may prevent hypocalcemia-related
complications.
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Introduction
Pseudohypoparathyroidism (PHP) describes a heteroge-
neous group of disorders characterized by hypocalcemia
and hyperphosphatemia, resulting from renal resistance to
PTH [1, 2].
Pseudohypoparathyroidism type Ia (PHP-Ia; MIM
103580) is characterized by end-organ resistance to PTH,
and to other hormones also signaling through G-protein-
coupled receptors, and a combination of defects termed
‘‘Albright Hereditary Osteodystrophy’’ (AHO), character-
ized by rounded face, obesity, short stature, brachydactyly,
and mental retardation [3]. These patients exhibit a
decrease in the bioactivity of Gsa, the alpha stimulatory
subunit of G-protein, as the result of inactivating mutations
in its encoding gene (GNAS; MIM 139320), located at
chromosome 20q13.3.
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Patients with pseudohypoparathyroidism type Ib (PHP-
Ib; MIM 603233) show renal resistance to PTH due to low/
absent Gsa activity, associated to the disruption of the
GNAS locus imprinting. These patients show, occasionally,
thyroid stimulating hormone (TSH) resistance and, typi-
cally lack AHO features [1]. The GNAS locus also encodes
four additional transcripts, XLas, NESP55, 1A (also
referred as A/B), and antisense (AS), which are imprinted
(Fig. 1) [4, 5]. The promoters and first exons of these four
transcripts are located within individual differentially
methylated regions (DMRs). AS, XLas, and 1A are tran-
scribed by the paternal allele, while NESP55 is transcribed
by the maternal allele. The Gsa promoter is not methylated
and the transcript is biallelically expressed in most tissues.
However, in the proximal renal tubules, thyroid, anterior
pituitary, and gonads, Gsa transcription from the paternal
allele undergoes tissue-specific silencing, being expressed
mainly by the maternal allele [6, 7].
PHP-Ib patients show loss of methylation at the mater-
nal 1A DMR [8, 9] and, apparently, this leads to a reduced/
absent Gsa expression in the proximal renal tubules [10].
This loss of methylation was associated to a maternally
inherited 3.0 kb deletion in up to 30 families with auto-
somal dominant PHP-Ib [9, 11, 12], or a 4.4 kb deletion in
one family [13], in the gene encoding syntaxin-16 (STX16;
MIM 603666), located 200 kb upstream from GNAS. Two
other families were shown to carry 4.0 and 4.7 kb deletions
in the maternal NESP55 DMR, which were associated to
methylation defects in the remaining GNAS DMRs [14].
These deletions at STX16 and NESP55 DMR comprise
putative cis-acting elements that control GNAS imprinting.
Broad methylation changes, resulting from yet unidentified
genetic causes, were also observed in several patients with
apparently sporadic PHP-Ib [9, 11, 12].
We identified four Portuguese patients with clinical
findings suggestive of PHP-Ib, and performed a compre-




Patient 1 was a 6-year-old Caucasian girl, when, in 1990,
she first presented at an Endocrinology Clinic because of
precocious pubarche and excess weight. Her TSH levels
were elevated at 11.8 mU/l (normal range [nr]: 0.5–
4.7 mU/l), free thyroxine (FT4) was 1.1 ng/dl (nr: 0.8–
2.2 ng/dl). Thyroid function normalized 1 year later. At the
age of 11, she was admitted to the hospital because of
repeated episodes characterized by loss of consciousness,
absence seizures, asymmetry of the mouth, loss of strength
in the lower limbs, and other hypocalcemia-related mani-
festations. On admission, her serum calcium (Ca) was
4.8 mg/dl (nr: 8.9–10 mg/dl), phosphorus (P) was 10.5 mg/
dl (nr: 2.3–4.7 mg/dl), PTH was 566 pg/ml (nr: 12–65 pg/
ml), and 1,25-dihydroxy vitamin D (1,25(OH)2D) was
38.5 pg/ml (nr: 18–62 pg/ml). Trousseau and Chvostek
signs were positive. Computed tomography (CT) scan of
the brain revealed bilateral calcifications of the basal nuclei
(Table 1). She was given calcium phosphate and
1,25(OH)2D. At the age of 18, still on medication, her
height was 1.63 m and weight was 58.4 kg (BMI = 22 kg/
m2). Her Ca was 8.8 mg/dl, P was 4.9 mg/dl, Mg was
2.1 mg/dl, and PTH was 171 pg/ml. When last seen, in
2008, at the age of 24, she was feeling well except for
occasional episodes of paresthesias, lightheadedness, and
nausea, usually associated with poor compliance with the
medication. Her Ca and PTH were, respectively, 8.6 mg/dl
and 127 pg/ml.
Patient 2, the younger half-sister of patient 1 (Fig. 2),
was first seen in 2003, at the age of 1 year, because of
obesity (length was 76 cm; weight was 12.8 kg) and
weakness of the superior limbs. She was hypothyroid (TSH
was 13.8 mU/l; FT4 was 0.9 ng/dl). Her serum ionized
calcium was 4.45 mg/dl (nr: 4.53–5.29 mg/dl) and PTH
was 26.3 pg/ml. She initiated medication with thyroxine.
At the last biochemical screening, in 2008, her Ca was
9.0 mg/dl, P was 5.9 mg/dl, and PTH was 401 pg/ml
(Table 1). Currently, at the age of 6, she is well developed
and she is still on thyroxine.
Both patients had no stigmata of AHO.
The older sister of patient 1, at the age of 26,
had normal Ca, P, and high PTH (86 pg/ml). No PHP-
related symptoms were observed in the remaining family
members.
Fig. 1 General organization of the GNAS locus. Exons are indicated
by closed boxes and introns are indicated by connecting lines. The
human GNAS locus generates four different sense transcripts
(NESP55, XLas, 1A, and Gsa), using four alternative first exons [1]
that splice onto a common set of downstream exons (2–13). In
addition, an antisense (AS) RNA is also produced. Promoters of the
imprinted transcripts are located within individual differentially
methylated regions (DMRs). Maternal (Mat) and paternal (Pat)
epigenotypes are represented above and below, respectively. Meth-
ylation is indicated by open circles and transcriptionally active
promoters are indicated by arrows in the direction of transcription.
Tissue-specific silencing of Gsa is indicated by a black cross
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Patient 3, a Caucasian female, was 11-year-old when, in
1985, she started complaining of ‘‘pins and needles’’,
headaches, lightheadedness, and crises of tetany, during
which she was unable to move her hands. She also had
absence seizures. However, the first symptom that led her
to medical attention occurred at the age of 12, when, during
a race, she started running in the opposite direction.
Hypocalcemia was diagnosed (no biochemical data from
this time was available). Since then, she was treated with
calcium and 1,25(OH)2D and the symptoms disappeared.
At the age of 20, she discontinued the medication. She
became pregnant at the age of 25. Early in pregnancy,
serum Ca was 6.8 mg/dl and P was 6.1 mg/dl. These values
went unheeded and no therapy was instituted. During
pregnancy and most of the nursing period she felt well.
After weaning, she started with crises of tetany similar to
those she had while adolescent and she had a seizure. Her
serum Ca, P, PTH, TSH, and total T4 were, respectively,
4.8 mg/dl, 7.4 mg/dl, 97 pg/ml, 5.4 mU/l, and 9.3 lg/dl
(T4 nr: 5.4–11.0 lg/dl). CT scan of the brain revealed
abundant symmetric calcifications in the thalamus and
striatum. Chvostek sign was positive (Table 1). She was
given calcium phosphate and l,25(OH)2D. The symptoms
and Chvostek sign disappeared and she felt well. She
became pregnant again at the age of 28. The dosage of
l,25(OH)2D was increased. During pregnancy her average
Ca, P, and PTH were, respectively, 7.8 mg/dl, 4.8 mg/dl,
and 23 pg/ml. Throughout nursing, the dosage of
1,25(OH)2D was reduced, and her average Ca, P, and PTH
were, respectively, 9.0 mg/dl, 4.8 mg/dl, and 6.1 pg/ml.
After weaning, she resumed baseline therapy and has been
well since. Her current BMI is 27 kg/m2. No features of
AHO were present. The biochemical screening for PHP in
her parents was negative.
Patient 4 was a 44-year-old Caucasian female when first
seen in 1997, at the Endocrinology Clinic, because of
weight gain. Her height was 1.56 m, weight 63 kg
(BMI = 25.9 kg/m2). She had been overweight since
childhood. She had three children at the ages of 17, 23, and
25 years. Since the age of 27, she had paresthesias of the
face, superior limbs, and extremities that became worse
with physical efforts. She also felt fatigue, myalgias, and
depression. This condition was interpreted as fibromyalgia.
She had no signs suggestive of AHO. On admission, her
serum Ca, P, PTH, TSH, and FT4 were, respectively,
6.9 mg/dl, 4.5 mg/dl, 269 pg/ml, 2.9 mU/l, and 0.96 ng/dl.














Patient 1 11 F 4.8 10.5 566 ?/? Bilateral calcifications of the basal nuclei
Patient 2 6 F 9.0 5.9 401 ND ND
Patient 3a 26 F 4.8 7.4 97 ?/ND Abundant symmetric calcifications of the
thalamus and striatum
Patient 4b 44 F 6.9 4.5 269 -/? Small calcification in the right lenticular nucleus
a Hypocalcemia was firstly detected at age 12, but initial biochemistry is not available
b Symptoms of hypocalcemia were first noticed at age 27, but initial biochemistry is not available
PTH parathormone, F female, CT computed tomography, - negative, ? positive, ND not done
Fig. 2 Analysis of 1A differentially methylated region (DMR), and
STX16 deletion screening in patients 1 and 2. PCR products from 1A
DMR were amplified from bisulfite-treated DNA from the patients,
their relatives, and an unrelated normal individual (N). In the absence
of methylation, the sequence from the bisulfite-treated DNA is
modified, removing the BstUI recognition sites. Enzymatic digestion
with BstUI results in fragments corresponding to the methylated
alleles (M) while the undigested product corresponds to the unme-
thylated alleles (U). In patients 1 and 2, loss of methylation was
detected at 1A DMR. Haplotype analysis using microsatellite markers
and SNPs, flanking and encompassing the previously reported STX16
deleted regions at chromosome 20q13.3, identified a lack of maternal
contribution at rs2296524 in patient 2. Long-range PCR amplification
of a 4.3 kb fragment from the STX16 gene yielded a 1.3 kb mutant
band in four family members, indicating that they were carriers of a
previously reported 3.0 kb STX16 deletion. The haplotype segregating
with the disease in this family is boxed. Open symbols represent
unaffected individuals, closed symbols represent affected individuals,
and dots indicate unaffected carriers of a mutant allele
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Chvostek sign was negative, but Trousseau was positive.
Brain CT scan revealed a small calcification in the right
lenticular nucleus (Table 1). She was treated with calcium
and 1,25(OH)2D. Currently, at the age of 53, she feels well.
Her Ca is 8.3 mg/dl and her PTH levels are 114 pg/ml. No
PHP-related symptoms were observed in her first-degree
family members.
Methylation analysis of the GNAS locus
This study was approved by the ethical committee of our
institution. Venous blood or saliva was obtained from the
patients and relatives, following written informed consent.
DNA was extracted following standard methods, and
modified with sodium bisulfite, using the Epitect Bisulfite
kit (Qiagen, Hilden, Germany). The four GNAS DMRs
(NESP55, AS, XLas, and 1A) were amplified by Nested
PCR and their differential methylation was assessed by
restriction enzymatic analysis with BstUI (CG;CG) (New
England Biolabs, Ipswich, MA, USA). Primer sequences
and PCR conditions are available on request. The ampli-
cons from DMRs 1A and NESP55 were cloned into the
pCR2.1-TOPO vector, using the TOPO TA Cloning kit
(Invitrogen, Paisley, PA, UK), and individual clones were
sequenced. The methylation analyses were also performed
in a normal unrelated individual (control).
Analysis of STX16 gene and NESP55 DMR
For haplotype analysis, single nucleotide polymorphisms
(SNPs), located at the previously reported deleted regions
of STX16 (50-rs6026436, rs6100156, rs2296524-30) and
NESP55 DMR (50-rs4812038, rs3761264, rs1800900,
rs1800905, rs55995056, rs3787497, rs6123832, rs4810147-
30), and at exon 5 from GNAS (rs7121), were PCR amplified,
and sequenced. Flanking microsatellite markers (cen-
D20S149, STX16, GNAS, D20S443-tel) were also genotyped
(NCBI; www.ncbi.nlm.nih.gov). DNA samples were
screened for the STX16 3.0 kb deletion, as previously
described [11]. A 9.0 kb region, involving NESP55 DMR
(from rs3761264 to rs4810147), was amplified using the
LongRange PCR Kit (Qiagen, Hilden, Germany) to screen
for deletions/insertions. Heterozygous SNPs were
sequenced in this fragment to confirm amplification of both
alleles. Smaller overlapping fragments, with sizes ranging
from 1.5 to 5.0 kb, were also amplified in this region. Primer
sequences and PCR conditions are available on request.
Results
Differential methylation was assessed by restriction anal-
ysis with BstUI. Patients 1 and 2, whom were half-sisters,
presented a loss of methylation at the maternal GNAS 1A
DMR (Fig. 2). A normal methylation pattern was observed
in the remaining DMRs, in the patients and relatives (data
not shown). To investigate the genetic defect underlying
this imprinting disruption, we screened the family for the
3.0 and 4.4 kb deletions, reported for the STX16 gene in
familial cases [11, 13]. Haplotype segregation analysis at
STX16 was not informative for patient 1, because she was
apparently homozygous for the three SNPs analyzed.
However, this analysis revealed the absence of the maternal
allele in patient 2, at rs2296524 (Fig. 2). Long-range PCR
amplification showed that patients 1 and 2, their mother
and grandfather, were carriers of the 3.0 kb deletion
(Fig. 2).
In patients 3 and 4, loss of methylation at 1A and AS
DMRs, and gain of methylation at NESP55 DMR, were
identified in the maternal allele. Loss of methylation at the
maternal XLas DMR was observed only in patient 4. A
normal methylation pattern was found in their family
members (Fig. 3). Segregation analysis did not identify
microdeletions at STX16 or NESP55 DMR in these two
patients (Fig. 3). Long-range PCR amplification was also
used to assess microdeletions. A fragment comprising 4.3
kb of the commonly deleted 3.0 kb region at STX16 was
amplified in the two patients, and no mutant bands were
detected (data not shown). A fragment encompassing
9.0 kb of NESP55 DMR was amplified in patients 3 and 4,
and in three normal individuals, used as controls. In all
amplifications, a single band was detected with the normal
size (data not shown). The bands amplified from both
patients DNA were sequenced, at two heterozygous poly-
morphic sites, which confirmed that both alleles were
amplified (data not shown). In order to search for small
deletions that could go unnoticed in a 9.0 kb gel band,
smaller overlapping fragments, with sizes ranging from 1.5
to 5.0 kb, were also amplified in this region, but no
abnormal bands were detected for both patients (data not
shown).
The broad methylation changes in patients 3 and 4, con-
sistent with a paternal epigenotype in the maternal allele,
could be the result of either a complete paternal isodisomy of
chromosome 20 (inheritance of a duplicated copy from a
single chromosome of the father) or a partial paternal isod-
isomy encompassing the GNAS locus, or NESP55 DMR only
[15]. Eight SNPs spanning an *10 kb region, which inclu-
ded NESP55 DMR, were genotyped in these two patients
(Fig. 3). Four of these SNPs (rs1800900, rs1800905,
rs55995056, and rs3787497) were located within an
*4.0 kb region, which has been suggested to carry a control
element for the GNAS imprinting [14]. Both patients were
heterozygous for several SNPs, including those located at the
4.0 kb region. Furthermore, these patients were also het-
erozygous for a 5-bp repeat at 1A DMR (Fig. 4). Therefore, it
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seems unlikely that these patients carry either a complete
isodisomy at chromosome 20, or a partial isodisomy at GNAS
locus, or NESP55 DMR only.
Paternal heterodisomy (inheritance of both chromo-
somes from the father) at chromosome 20 could also
account for the abnormal GNAS methylation pattern in the
patients 3 and 4 [16]. However, in patient 3, biparental
inheritance at STX16/GNAS excluded heterodisomy
(Fig. 3a). In patient 4, given that the DNA from her father
was not available to study, paternal heterodisomy, involv-
ing the entire chromosome 20, could only be excluded by
the detection of a normal methylation status at the
imprinted NNAT gene [17], located at chromosome
20q11.2-q12 (data not shown).
Regarding the inheritance of the affected alleles, both
offspring of patient 3 shared a maternal haplotype covering
STX16 and GNAS, transmitted by the grandmother. How-
ever, they did not present GNAS methylation changes
(Fig. 3a). The son of patient 4, who inherited the STX16–
GNAS haplotype, transmitted by the maternal grandmother,
did not present methylation changes either (Fig. 3b).
The methylation changes found at 1A and NESP55
DMRs, in patients 1, 3, and 4, were confirmed and exten-
ded, by cloning the same amplicons and sequencing all
CpGs (Fig. 4).
The identification of imprinting defects at the GNAS
locus confirmed the diagnosis of PHP-Ib in the four
patients.
Discussion
In this study, we identified three unrelated patients pre-
senting hypocalcemia, hyperphosphatemia, elevated serum
levels of PTH, and no visible features of AHO, suggesting
the diagnosis of PHP-Ib. An affected oligosymptomatic
sister was also identified (patient 2). In order to investigate
the molecular defects underlying PHP in these patients, a
comprehensive analysis of GNAS and STX16 loci was
undertaken.
Loss of methylation was detected at GNAS 1A DMR, in
patients 1 and 2, resulting from the autosomal dominant
Fig. 3 Analysis of GNAS differentially methylated regions (DMRs),
and haplotype segregation analysis at STX16/GNAS loci, in patients 3
and 4. PCR products from each DMR were amplified from bisulfite-
treated DNA from the patients, their relatives, and an unrelated
normal individual (N). In the absence of methylation, the sequence
from the bisulfite-treated DNA is modified, removing the BstUI
recognition sites. Enzymatic digestion with BstUI resulted in
fragments corresponding to the methylated alleles (M) while the
undigested product corresponds to the unmethylated alleles (U). a
Haplotypes for STX16/GNAS loci are shown for patient 3 and her
family, and the patient’s maternal haplotype is boxed. In patient 3,
gain of methylation at NESP55 DMR and loss of methylation at AS
and 1A DMRs were detected, at the maternal allele, whereas the
methylation status of XLas DMR appeared unchanged. The patient’s
relatives presented a normal methylation pattern. b Haplotypes for
STX16/GNAS loci are shown for patient 4 and her family, and the
boxed haplotype represents the patient’s maternal haplotype. Patient 4
had loss of methylation at AS, XLas, and 1A DMRs and gain of
methylation at NESP55 DMR. The patient’s mother and offspring
showed a normal methylation pattern. Open symbols represent
unaffected individuals, closed symbols represent affected individuals,
and asterisks indicate individuals that were not investigated
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inheritance of a previously reported 3.0 kb deletion in the
STX16 gene, comprising a putative cis-acting control ele-
ment for the imprinting of the GNAS locus [11]. The
paternal inheritance of the deletion in their mother and,
possibly, in the grandfather, explains the lack of methyla-
tion defects in these two unaffected carriers. In patients 3
and 4, methylation changes were detected at DMRs
NESP55, AS, 1A and, also at XLas, in patient 4, consistent
with a paternal epigenotype in the maternal allele. This
suggested either a familial form of PHP-Ib, associated with
NESP55 DMR deletions, or a sporadic manifestation of the
disease [9, 14, 15]. However, we found no evidence that
these patients carried deletions at STX16 or NESP55 DMR.
Haplotype analysis showed that both offspring of patient 3,
and the son of patient 4, inherited the grandmaternal alleles
at the STX16/GNAS loci, but did not present GNAS
imprinting changes. These results point to several different
possibilities regarding the genetic mechanism causing
imprinting disruption in the two patients: (a) a putative
mutation located at another, yet unidentified, locus distant
from the GNAS chromosomal region; (b) a post-zygotic
mutation at the STX16/GNAS loci, leading to mosaicism;
(c) a failure in the imprinting erasure and reset at the
maternal germ cells; and (d) a complete or partial paternal
iso/heterodisomy at chromosome 20.
The hypothesis of either a complete isodisomy at
chromosome 20, or a partial isodisomy at the GNAS locus,
or NESP55 DMR only, is poorly sustained by the haplo-
type data, since heterozygosity was identified for several
polymorphisms located at a 10 kb region encompassing
NESP55 DMR, and also 1A DMR. The possibility of a
paternal heterodisomy of chromosome 20 was ruled out in
patient 3, by the biparental inheritance of alleles at STX16/
GNAS and, in patient 4, by the detection of a normal
methylation status at the imprinted NNAT gene. However,
since NNAT is located centromeric to GNAS, a telomeric
paternal heterodisomy encompassing the GNAS locus could
not be excluded in patient 4. Indeed, patients with
imprinting disorders, carrying biparental alleles with seg-
mental heterodisomy, have been previously reported [16].
As regards to the clinical onset of the disease, in patients 1
and 3, hypocalcemia was first observed at the ages of 11–
12 years. Patient 2, at the age of 6, had normal calcium levels
but her PTH was already very high. In patient 4, nonspecific
symptoms started by the age of 27, but hypocalcemia was
only detected at the age of 44. A review of published clinical
data of patients with PHP-Ib revealed that the mean age of
diagnosis is 11.6 ± 1.60 years in symptomatic female
patients, carrying the 3.0 kb maternal deletion at STX16, and
9.5 ± 1.06 years in female sporadic patients [18]. The rea-
sons why the resistance to PTH and hypocalcemia develop
only at a certain age are unclear. Patient 1 had a normal
concentration of 1,25(OH)2D at a time when she was frankly
symptomatic and hypocalcemic. A similar case was reported
by Bastepe et al. [15]. These are noteworthy findings, con-
sidering that most patients with pseudohypoparathyroidism
present with low concentrations of 1,25(OH)2D, as expected
from the reduced responsiveness of their proximal tubules to
PTH [1, 2]. The older sister of patients 1 and 2 presented
mildly elevated levels of PTH, together with normocalce-
mia, at the age of 26. Establishing a non-carrier status in this
patient was important, as it showed that, rather than PHP-Ib,
the high PTH levels were probably due to secondary
hyperparathyroidism.
Two of the four patients in the present series (patients 1
and 2) had subclinical hypothyroidism, possibly due to
resistance to TSH. An overall analysis of the clinical fea-
tures associated to the defective GNAS imprinting shows a
consistent pattern concerning the symptoms associated to
PTH resistance [11, 18]. However, additional manifesta-
tions of hormone resistance (e.g., TSH), related to tissue-
Fig. 4 Characterization of methylation defects in the CpG islands
from 1A and NESP55 differentially methylated regions (DMRs) in
patients 1, 3, and 4. Since both patients 1 and 2 inherited the same
genetic defect (STX16 deletion), the epigenetic alteration at 1A DMR
was not further characterized in patient 2. PCR products from 1A
DMR, amplified from bisulfite-treated DNA, were cloned and
sequenced for extended methylation analysis. Each row of circles
represents one clone. Methylated CpGs are indicated by closed circles
and unmethylated CpGs by open circles. In patients 1, 3, and 4, a loss
of methylation in 1A DMR was shown by the predominance of
unmethylated CpGs in all the clones. Patients 3 and 4 were
heterozygous for a 5-bp repeat polymorphism that includes two
additional CpGs, represented by two circles. Patient 1 and the normal
control were homozygous for this polymorphism. The analysis of
CpG methylation was extended to NESP55 DMR in patient 3 and
patient 4. In both cases, methylation was observed in all clones
sequenced, indicating a gain of methylation at NESP55 DMR. A
normal methylation pattern was observed in the unrelated normal
individual, in whom the sequenced clones revealed the presence of
methylated and unmethylated alleles, for both 1A and NESP55 DMRs
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specific imprinting of Gsa, are variable or absent among
PHP-Ib patients, as shown in this, and other reports [12,
19].
This study describes the first clinical and genetic char-
acterization of Portuguese patients with PHP-Ib. The
identification of imprinting defects allowed the differential
diagnosis between PHP-Ib and other PHP variants. Since
clinical and biochemical findings can be quite variable,
mildly affected or young asymptomatic patients with PHP-
Ib may not be readily identified. As shown in this study, the
identification of hereditary forms of PHP-Ib is important
for clinical management and genetic counseling. The
detection of a STX16 deletion in patients 1 and 2 indicated
that their offspring will have a 50% chance of inheriting the
disease. On the other hand, since the mechanisms under-
lying broad GNAS methylation changes in patients 3 and 4,
are still unknown, as in most apparently sporadic cases, the
presence of germline alterations in distinct loci cannot not
be ruled out. Nonetheless, the absence of methylation
defects in these patients’ offspring allowed their exclusion
from further clinical screening.
Further genetic studies on PHP-Ib cases are needed to
unveil novel somatic and germline events involved in the
control of GNAS imprinting.
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